Similarly, STING agonists incorporated within lipid nanoparticles (LNP) that target DNGR‐1 stimulate cDC1 to promote anti‐tumour immune responses and enhance the response to ICB in mice [140]. The gene discussed is CLEC9A; the disease is neoplasm.